Biopharma's Technology and Capital Partner
Technology and financing solutions to advance tomorrow’s medicines
A specialist
in healthcare investing
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 100 partnered commercial and development stage programs. We also maintain and license our Captisol® and NITRICIL™ technology platforms with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world.
Diversified Portfolio
Our portfolio includes programs that span disease areas such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and many rare conditions. Today we own economic rights to more than 30 commercial programs, which are marketed in more than 70 countries.
By the Numbers
assets
partnered programs
Orchestra BioMed Secures $70 Million from Ligand and Medtronic
Capital will help advance Orchestra’s late-stage partnered cardiology programs AVIM therapy and Virtue SAB, two novel high-impact, device-based therapies
Pelthos Therapeutics to Merge with Channel Therapeutics
Combined company to focus on launching Pelthos’ ZELSUVMI™, for which Ligand will receive a 13% royalty on worldwide sales.
Ligand Leads $75 Million Financing in Castle Creek
Transaction provides Ligand a high-single digit royalty on worldwide sales of D-Fi, Castle Creek’s lead candidate for dystrophic epidermolysis bullosa.